NCT01362218

Brief Summary

This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of the reference products (simvastatin, ramipril, acetylsalicylic acid) Approximately 350 subjects will be screened, 266 randomized in order about 238 subjects to finish the study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
107

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Oct 2010

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 30, 2011

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
Last Updated

April 24, 2013

Status Verified

April 1, 2013

Enrollment Period

1.5 years

First QC Date

May 26, 2011

Last Update Submit

April 23, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Difference in LDL-cholesterol levels between the basal and the final visit of treatment period.

    Day 56

Secondary Outcomes (4)

  • • Difference in VLDL-cholesterol levels between the basal and the final visit of treatment period.

    Day 56

  • • Difference in HDL-cholesterol levels between the basal and the final visit of treatment period.

    Day 56

  • • Difference in total cholesterol levels between the basal and the final visit of treatment period.

    Day 56

  • • Difference in triglyceride levels between the basal and the final visit of treatment period

    Day 56

Study Arms (2)

Fixed Dose Combination Pill

EXPERIMENTAL

A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)

Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)

Simvastatin

ACTIVE COMPARATOR

Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid

Drug: Simvastatin, ramipril, acetylsalicylic acid

Interventions

A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.

Fixed Dose Combination Pill

A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks

Simvastatin

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female subjects aged ≥18 and \<75 years.
  • Previously untreated or not treated with fibrates during the last 6 weeks or with any other lipid lowering drug for the last 4 weeks.
  • LDL-cholesterol ≥130 and ≤220 mg/dL.
  • Systolic blood pressure ≥120 and \<160 mmHg and diastolic blood pressure ≥70 and \<100 mmHg.
  • Provide written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clinic

Barcelona, Spain

Location

MeSH Terms

Conditions

Hyperlipoproteinemia Type II

Interventions

Blood CirculationAspirinSimvastatinRamipril

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperlipoproteinemiasHyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Cardiovascular Physiological PhenomenaCirculatory and Respiratory Physiological PhenomenaSalicylatesHydroxybenzoatesPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsLovastatinNaphthalenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2011

First Posted

May 30, 2011

Study Start

October 1, 2010

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

April 24, 2013

Record last verified: 2013-04

Locations